Product
Risdiplam
Aliases
Evrysdi, Evrysdi®, RO7034067, RO7034067, Evrysdi
Name
EVRYSDI
INN Name
Risdiplam
FDA Approved
Yes
8 clinical trials
1 organization
3 indications
1 document
Indication
Spinal Muscular AtrophyIndication
Muscular AtrophyIndication
spinalClinical trial
An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric Patients With Spinal Muscular AtrophyStatus: Active (not recruiting), Estimated PCD: 2024-12-27
Clinical trial
A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Infants With Type 1 Spinal Muscular AtrophyStatus: Completed, Estimated PCD: 2019-11-14
Clinical trial
An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophyStatus: Active (not recruiting), Estimated PCD: 2023-02-20
Clinical trial
A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular AtrophyStatus: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
Long-Term Follow-Up Study of Patients With Spinal Muscular Atrophy Receiving Risdiplam TreatmentStatus: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular AtrophyStatus: Recruiting, Estimated PCD: 2026-06-27
Clinical trial
Investigating NMJ Defects in SMA Following Central and Peripheral SMN RestorationStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy PatientsStatus: Completed, Estimated PCD: 2019-09-06
Document
DailyMed Label: EVRYSDIOrganization
Genentech Inc.